
Edwards Lifesciences Q3 2026 Results: Net Income $308 Million on Revenue of $1.72 Billion
Edwards Lifesciences (NYSE: EW) reported GAAP revenue of $1.72 billion and GAAP net income of $307.5 million attributable to the company for the third quarter of 2026, it said on 4 Nov 2026. Diluted EPS was $0.53 on a GAAP basis. Adjusted EPS, a company-defined measure that excludes items such as litigation expenses and an impairment charge, was $0.80.
- US stocks
- Earnings